Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Home
/
update
/
details

Pillar Biosciences Launches FDA-Approved oncoReveal™ CDx Solid Tumor NGS Kit at Molecular Pathology Laboratory Network, Inc.

NextEdge Admin

01 Aug 2024

3 min 6 sec

Molecular Pathology Laboratory Network, Inc.,NGS testing,CDx

Pillar Biosciences, Inc., a leader in Decision Medicine™, has announced that Molecular Pathology Laboratory Network, Inc. (MPLN) is the first national molecular reference laboratory to verify and launch the oncoReveal™ CDx pan-cancer solid tumor IVD kit. This kit, which has received FDA PMA approval, enables comprehensive tumor profiling for 22 clinically relevant genes across all solid tumors. It includes specific companion diagnostic claims for KRAS in colorectal cancer and EGFR in non-small cell lung cancer. The oncoReveal™ CDx kit features a rapid single-day workflow and can be used by any clinical laboratory equipped with an Illumina MiSeq™ Dx platform, allowing an integrated sample-to-report time of just 48 hours and processing up to 46 clinical samples per run.

Dr. Roger Hubbard, CEO of MPLN, highlights the importance of this diagnostic tool in swiftly identifying cancer patients for first-line targeted therapies or clinical trials. MPLN verified the full IVD assay within two weeks of training, showcasing its quick implementation. MPLN plans to collaborate with its physician network and biopharma partners to integrate this innovative solid tumor IVD product into clinical practice.

Dan Harma, Chief Commercial Officer of Pillar Biosciences, addresses the increasing regulatory pressures on CLIA-certified molecular reference laboratories and underscores the benefits of the oncoReveal™ CDx. This FDA-approved assay can be rapidly verified and performed in any lab with an Illumina MiSeq™ Dx platform, reducing delays in patients receiving targeted therapy and improving overall patient care.

Pillar Biosciences focuses on Decision Medicine™, utilizing next-generation sequencing (NGS) technology to enhance precision therapy selection, from tumor profiling to therapy selection and recurrence monitoring. Their proprietary SLIMamp® and PiVAT® technologies streamline the testing process, lowering diagnostic costs and improving access to NGS testing globally. MPLN, a pioneer in laboratory medicine since 1989, specializes in women's health and oncology, offering advanced molecular diagnostics, specialty pathology, and superior customer service to healthcare providers nationwide.